Share-based Payment Arrangement, Expense of ARROWHEAD PHARMACEUTICALS, INC. from 30 Sep 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2011 to 30 Sep 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $13,599,000, a 25% decline year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $54,848,000, a 18% decline year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2025 was $54,848,000, a 18% decline from 2024.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $67,097,000, a 14% decline from 2023.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $78,130,000, a 35% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $54,848,000 $13,599,000 -$4,514,000 -25% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q2 2025 $59,362,000 $11,993,000 -$2,718,000 -18% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q3
Q1 2025 $62,080,000 $15,081,000 -$1,507,000 -9.1% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q2
Q4 2024 $63,587,000 $14,175,000 -$3,510,000 -20% 01 Oct 2024 31 Dec 2024 10-Q 10 Feb 2025 2025 Q1
Q3 2024 $67,097,000 $18,113,000 -$68,000 -0.37% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q2 2024 $67,165,000 $14,711,000 -$5,236,000 -26% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q3
Q1 2024 $72,401,000 $16,588,000 -$4,025,000 -20% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q2
Q4 2023 $76,426,000 $17,685,000 -$1,704,000 -8.8% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025 2025 Q1
Q3 2023 $78,130,000 $18,181,000 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025 2025 FY
Q2 2023 $19,947,000 -$13,443,000 -40% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q3
Q1 2023 $20,613,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q2
Q4 2022 $19,389,000 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024 2024 Q1
Q2 2022 $33,390,000 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q3
Q4 2017 $7,559,694 $2,092,541 -$331,901 -14% 01 Oct 2017 31 Dec 2017 10-Q 09 Feb 2018 2018 Q1
Q3 2017 $7,891,595 $2,009,694 -$2,038,155 -50% 01 Jul 2017 30 Sep 2017 10-K 12 Dec 2017 2017 FY
Q2 2017 $9,929,750 $1,713,228 -$1,037,557 -38% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2017 2017 Q3
Q1 2017 $10,967,307 $1,744,231 -$672,608 -28% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2017 2017 Q2
Q4 2016 $11,639,915 $2,424,442 +$44,099 +1.9% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018 2018 Q1
Q3 2016 $11,595,816 $4,047,849 +$520,961 +15% 01 Jul 2016 30 Sep 2016 10-K 12 Dec 2017 2017 FY
Q2 2016 $11,074,855 $2,750,785 +$264,711 +11% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q3
Q1 2016 $10,810,144 $2,416,839 +$211,760 +9.6% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q2
Q4 2015 $10,598,384 $2,380,343 +$365,487 +18% 01 Oct 2015 31 Dec 2015 10-Q 06 Feb 2017 2017 Q1
Q3 2015 $10,232,897 $3,526,888 01 Jul 2015 30 Sep 2015 10-K 12 Dec 2017 2017 FY
Q2 2015 $2,486,074 +$1,415,443 +132% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q3
Q1 2015 $2,205,079 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q2
Q4 2014 $2,014,856 +$1,493,718 +287% 01 Oct 2014 31 Dec 2014 10-Q 09 Feb 2016 2016 Q1
Q2 2014 $1,070,631 +$707,038 +194% 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2014 2014 Q3
Q4 2013 $521,138 +$125,464 +32% 01 Oct 2013 31 Dec 2013 10-Q 04 Feb 2014 2014 Q1
Q2 2013 $363,593 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q3
Q4 2012 $395,674 +$143,796 +57% 01 Oct 2012 31 Dec 2012 10-Q 04 Feb 2014 2014 Q1
Q4 2011 $251,878 01 Oct 2011 31 Dec 2011 10-Q 13 Feb 2013 2013 Q1

ARROWHEAD PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $54,848,000 -$12,249,000 -18% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025 2025 FY
2024 $67,097,000 -$11,033,000 -14% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025 2025 FY
2023 $78,130,000 -$42,763,000 -35% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025 2025 FY
2022 $120,893,000 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024 2024 FY
2017 $7,891,595 -$3,704,221 -32% 01 Oct 2016 30 Sep 2017 10-K 12 Dec 2017 2017 FY
2016 $11,595,816 +$1,362,919 +13% 01 Oct 2015 30 Sep 2016 10-K 12 Dec 2017 2017 FY
2015 $10,232,897 +$4,536,724 +80% 01 Oct 2014 30 Sep 2015 10-K 12 Dec 2017 2017 FY
2014 $5,696,173 +$4,159,902 +271% 01 Oct 2013 30 Sep 2014 10-K 14 Dec 2016 2016 FY
2013 $1,536,271 +$294,867 +24% 01 Oct 2012 30 Sep 2013 10-K 14 Dec 2015 2015 FY
2012 $1,241,404 -$135,517 -9.8% 01 Oct 2011 30 Sep 2012 10-K 18 Dec 2013 2013 FY
2011 $1,376,921 01 Oct 2010 30 Sep 2011 10-K 28 Dec 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.